Home » Newsletters » BioWorld Science

BioWorld Science

April 21, 2010

View Archived Issues

FIBREX Medical discloses novel cell adhesion inhibitors

Roche discovers novel NS5B inhibitors for HCV infection

Abbott describes new indole and indoline derivatives with neurotrophic activity

NeuroSearch identifies novel potassium channel modulators

Biotechnology Research claims new PGE2, NMDA and MC receptor antagonists

Data on vipadenant warrant further development in moderate- to late-stage PD patients

Quinacrine does not extend survival in sporadic Creutzfeldt-Jakob disease

Ongoing tacrolimus treatment beneficial for atopic dermatitis

ONO-8539 for overactive bladder well tolerated in healthy adults

Decline of mGlu5 receptor binding as a marker of early Alzheimer's disease

First phase III trial of ThromboGenics' microplasmin for eye disease meets primary endpoint

Topline phase III data disclosed on Benlysta in systemic lupus erythematosus

QLT reports interim phase Ib data on QLT-091001 in Leber's congenital amaurosis

Roche advances RG-7348 for hepatitis C into the clinic

LCL-161 well tolerated in ongoing first-in-human study

SCH-900776 sensitizes cancer cells to hydroxyurea and gemcitabine

Gilead provides update on development of fixed-dose Truvada/TMC-278 regimen for HIV

Cornerstone receives FDA clearance for phase I trial of CPI-613 in hematologic malignancies

Cadence Pharmaceuticals to resubmit NDA for Ofirmev injection

EntreMed completes registered direct offering to fund clinical development of ENMD-2076

Acorda plans phase I trial of GGF2 for treatment of heart failure

European Joulferon MAA for chronic hepatitis C withdrawn

Southern Research and Vivo Biosciences sign promotion and comarketing agreement

ChromoCure and GRG sign letter of intent in merger and acquisition agreement

Elan considers dividing Elan Drug Technologies into two companies

Abbott completes tender offer to finalize acquisition of Facet Biotech

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...